Effects of cidofovir on a novel cell-based test system for recurrent respiratory papillomatosis

Head and Neck

Volumn 29, Issue 8, 2007, Pages 741-750

  Donne, Adam J ^a,b   Hampson, Lynne ^a   He, Xiao T ^a   Rothera, Michael P ^c   Homer, Jarrod J ^b   Hampson, Ian N ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^c ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

Cidofovir; HPV16; HPV6; Respiratory papillomatosis

Indexed keywords

CIDOFOVIR;

ARTICLE; CELL LINE; CONTROLLED STUDY; DRUG EFFECT; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 6; NUCLEOTIDE SEQUENCE; PAPILLOMATOSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; TUMOR GROWTH; TUMOR RECURRENCE; UTERINE CERVIX CARCINOMA;

ANTIVIRAL AGENTS; BLOTTING, WESTERN; CYTOSINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 6; HUMANS; OTORHINOLARYNGOLOGIC NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED;

EID: 34547936181     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.20572     Document Type: Article

References (24)

1. Strong M, Vaughan CW, Healy B, Cooperband S, Clemente M. Recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol 1976;85:508-516.
2. Mounts P, Shah KV, Kashima HK. Viral aetiology of juvenile and adult onset squamous papilloma of the larynx. Proc Natl Acad Sci U S A 1982;79:5425-5429.
3. Benjamin B, Parsons DS. Recurrent respiratory papillomatosis: a 10 year study. J Laryngol Otol 1988;102:1022-1028.
4. Derkay CS. Task force on recurrent respiratory papillomas. A preliminary report. Arch Otolaryngol Head Neck Surg 1995;121:1386-1391.
5. Gillison ML. Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical and molecular entity. Semin Oncol 2004;31:744-754.
6. Stanley MA. Immunobiology of papillomavirus infections. J Reprod Immunol 2001;52:45-59.
7. Crook T, Fisher C, Masterson PJ, Vousden KH. Modulation of transcriptional regulatory properties of p53 by HPV E6. Oncogene 1994;9:1225-1230.
8. Zerfass K, Schulze A, Spitkovsky D, Friedman V, Henglein B, Jansen-Durr P. Sequential activation of cyclin E and cyclin A gene expression by human papillomavirus type16 E7 through sequences necessary for transformation. J Virol 1995;69:6389-6399.
9. Scheffner M, Huibregtse JM, Howley PM. Identification of a human ubiquitin-conjugating enzyme that mediates the E6-AP-dependent ubiquitination of p53. Proc Natl Acad Sci USA 1994;91:8797-8801.
10. Crook T, Fisher C, Masterson PJ, Vousden KH. Modulation of transcriptional regulatory properties of p53 by HPV E6. Oncogene 1994;9:1225-1230.
11. De Clercq E. Therapeutic potential of cidofovir (HPMPC, Vistide) for the treatment of DNA virus (i.e. herpes-, papova-, pox-, and adenovirus) infections. Verh K Acad Geneeskd Belg 1996;58:19-47.
12. Andrei G, Snoek R, Schols D, De Clerq E. Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells. Oncol Res 2001;12:397-408.
13. Sirianni N, Wang J, Ferris RL. Antiviral activity of cidofovir on a naturally human papillomavirus-16 infected squamous cell carcinoma of the head and neck (SCCHN) cell line improves radiation sensitivity. Oral Oncol 2005;41:423-428.
14. Hampson L, El Hady ESA, Moore JV, Kitchener H, Hampson IN. The HPV16 E7 and E7 proteins and the radiation resistance of cervical carcinoma. FASEB J 2001;15:1445-1447.
15. Sambrook J, Russell DW. Molecular cloning: a laboratory manual, 3rd ed. New York: CSHL Press; 2001. Vol. 2, p 12.31.
16. Crook T, Wrede D, Vousden KH. p53 point mutation in HPV negative human cervical carcinoma cell lines. Oncogene 1991;6:873-875.
17. Wrede D, Tidy JA, Lane D, Vousden KH. Expression of RB and p53 proteins in HPV-positive and HPV-negative cervical carcinoma cell lines. Mol Carinog 1991;4:171-175.
18. Abdulkarim B, Sabri S, Deutsch E, et al. Antiviral agent cidofovir restores p53 function and enhances the radiosensitivity in HPV-associated cancers. Oncogene 2002; 21: 2334-2346.
19. Naiman AN, Roger G, Gagnieu MC, et al. Cidofovir plasma assays after local injection in respiratory papillomatosis. Laryngoscope 2004;114:1151-1156.
20. Fennema JSA, Van Ameijden EJC, Coutinho RA, Van den Hock AJAR. HIV, sexually transmitted diseases and gynaecologic disorders in women: increased risk for genital herpes and warts among HIV-infected prostitutes in Amsterdam. AIDS 1995;9:1071-1078.
21. Nunez DA, Astley SM, Lewis FA, Wells M. Human papilloma viruses: a study of their prevalence in the normal larynx. J Laryngol Otol 1994;108:319-320.
22. Mandell DL, Arjmand EM, Kay DJ, Casselbrant ML, Rosen CA. Intralesional cidofovir for pediatric recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg 2004;130:1319-1323.
23. Bergler WF, Gotte K. Current advances in the basic research and clinical management of juvenile-onset recurrent respiratory papillomatosis. Eur Arch Otorhinolaryngol 2000;257:263-269.
24. Wemer RD, Lee JH, Hoffman HT, Robinson RA, Smith RJ. Case of progressive dysplasia concomitant with intralesional cidofovir administration for recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol 2005;114:836-839.